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Background
In a non-inferiority study where the aim is to compare
a reduced treatment duration there is a choice of two
randomisation time-points. Patients can be randomised
at the end of the reduced treatment period to continue
or not to the standard duration. This is optimum for
maximising compliance, but has the disadvantage for
the patient that treatment duration is not known from
the outset. It is also more difficult to implement and,
because of patients dropping out prior to randomisa-
tion, may result in an unrepresentative patient group.
The alternative is to randomise patients prior to start-
ing treatment.
Methods
SCOT is a large (9500) phase III randomised non-
inferiority study comparing 6 versus 3 months adjuvant
treatment in colorectal cancer. In the first year of
recruitment centres were randomised to either rando-
mise patients prior to treatment (Up-front:U) or after
they had completed 3 months of treatment (Delayed:
D). In June 2009 the performance of the two
approaches was reviewed in terms of recruitment rate,
compliance and drop-out by the Trial Steering Com-
mittee (TSC) and the recommendation was made to
change all sites to U. Using data to the end of 2010 we
have looked at recruitment before/after the change,
restricted to centres open >3 months prior to the
change date. Updated drop-out information is also
provided.
Results
215 patients were registered for D and of these 159 were
randomised; a drop-out rate of 26% (95% confidence
interval [ci] 21-32%). This drop-out rate is higher than
the general rate of patients stopping treatment at 3
months 18% (95% ci 16-21%).
For the 41 centres allocated to D the median [inter-
quartile-range] randomisation rate prior to changing to
U was 4.09 [1.29-7.09] patients/centre/year; after chan-
ging to U the equivalent figures were 8.87 [4.77 –
15.34]. This increase is statistically significant (p<.001).
For the 36 centres allocated to U the median [inter-
quartile-range] randomisation rate prior to the date the
D centres changed to U was 5.21 [3.56-11.55] patients/
centre/year; post this date the equivalent figures were
7.52 [2.22 – 14.31]. This increase was not statistically
significant (p=.121).
T h ei n c r e a s ei nr e c r u i t m e nt rate in the D centres is
much higher than in the U centres post the randomisa-
tion change date (p=.001, test for interaction).
Conclusions
In 2009 the TSC recommended that SCOT continue
with up-front randomisation only. This was based on
the higher randomisation rate with U and a high drop-
out rate with D. Further data has endorsed that
recommendation.
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